Preclinical studies show that CAR-Ms targeting HER2 or CD20 can decrease tumour burden via phagocytosis, secretion of pro-inflammatory cytokines, and antigen presentation [36, 116, 118]. This evidence concerns the gene ERBB2 and neoplasm.